Achilles’ truncal neoantigens

How Achilles is using ‘truncal’ neoantigens to drive a TIL-derived therapy

Achilles Therapeutics Ltd. is developing a personalized T cell therapy that uses “truncal” neoantigens expressed in all tumor cells to drive T cells selected from tumor-infiltrating lymphocytes (TILs).

Neoantigen discovery is fueling a burst of cancer immunotherapy companies taking advantage of the tumor specificity of the antigens, bolstered by evidence that high neoantigen burden correlates with a positive response to immune therapies and prolonged survival (see “Neo

Read the full 660 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE